Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced Medicare coverage for the DecisionDx®-Melanoma test that predicts risk of metastatic disease and helps to guide use of sentinel lymph node biopsy (SLNB) in patients with cutaneous melanoma.
Read MoreCareMetx, a technology-enabled hub services provider for pharmaceutical and biotechnology manufacturers, today announced they have acquired VirMedica, the leader in e-access technology solutions designed to streamline patient access to life-enhancing therapies.
Read MoreHealthQuest participated in a $120M Series B financing into Ajax Health, a platform company focused on investing in and accelerating innovative medical technologies that address significant unmet clinical needs.
Read MoreHealthQuest Capital portfolio company Avedro, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa® drug formulations.
Read MoreHealthQuest led a $25 million investment into CleanSlate, a national leader in outpatient pharmacological treatment for the chronic disease of addiction.
Read MoreAmerican Well, a leading U.S. telehealth provider, today announced that it has entered into a definitive agreement to acquire Avizia, a leading player in acute care telehealth.
Read MoreHealthQuest led a $26.5 million investment into BioIQ, the leading platform for orchestrating health testing programs and biometric screening events across multiple vendors. Additionally, BioIQ utilizes multi-channel communication tools for engaging and motivating participants. HealthQuest was joined in this investment by Arboretum Ventures and select insiders.
Read MoreTrice Medical completes its first successful case performed in the United Kingdom, after receiving CE Mark of approval in Europe for the mi-eye 2™, as well as entry into Health Canada.
Read MoreHealthQuest Capital, EW Healthcare partners and Madryn Asset Management invested an additional $7 million in Venus Concept concurrent with the completion of the acquisition of NeoGraft. NeoGraft is an industry leader in the area of hair restoration technologies. Venus Concept's industry first and only subscription-based business model, combined with its global reach in over 60 countries and 27 direct global offices, will create a significant opportunity to expand the overall combined businesses of both NeoGraft and Venus Concept.
Read MoreHealthQuest led a $20 million investment into Springbuk, the leading employer-facing health intelligence software. HealthQuest was joined in this investment by Echo Health Ventures and Lewis & Clark Ventures.
Springbuk was founded in 2015 by Rod Reasen and Phil Daniels, co-founders of the Healthiest Employers awards program, with the mission to empower employers to lower their healthcare costs by harnessing their health data. Today, over 1,000 employers use Springbuk’s software to glean actionable insights to improve their population’s health.
Read MoreCastle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.
Read MoreHealthQuest Capital Managing Partner, Dr. Garheng Kong, was selected as one of 21 healthcare industry leaders to participate in the Aspen Insitute's Health Innovators Fellowship. He and the other fellows will participate in a two-year Fellowship designed to strengthen the leadership of innovators across the US health care ecosystem and challenge them to create new approaches to improve the health and well-being of all Americans.
Read More
Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that it has entered into a definitive agreement to acquire Spirox, Inc., a privately-held ENT medical technology company that develops, manufactures and markets the LATERA™ Absorbable Nasal Implant, a minimally invasive option for ENTs and facial plastic surgeons to treat nasal airway obstruction.
Read MoreBiotheranostics, Inc. today announced new data from two new studies further demonstrating the importance of BCI in clinical practice. The studies are being presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago this week.
Read MoreTrice Medical announced today that it closed a $19.3 million Series C financing and will use the proceeds to accelerate and expand the company's U.S. market penetration for mi-eye2™, R&D, sales, marketing and key international regulatory approvals. Smith & Nephew (LSE:SN, NYSE: SNN) has taken a minority stake joining a consortium of current investors including HealthQuest.
Read MoreAvedro, Inc., an ophthalmic pharmaceutical and medical device company and world leader in corneal remodeling, today announced that it secured a combined $42 million in equity and debt financing. The equity financing was led by HealthQuest Capital, with strong support from existing investors OrbiMed Advisors and InterWest Partners.
Read MoreFriendswood, TX – March 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Blue Cross Blue Shield Association Evidence Street™ has issued a positive assessment of DecisionDx®-UM, the Company’s gene expression profile (GEP) test to determine prognosis (metastatic potential) in patients diagnosed with uveal melanoma (UM). Evidence Street provides objective information to healthcare and managed care professionals based on clinical and scientific evidence and evaluates whether a technology could improve net health outcomes
Read More
